Funding

Oncostellae is owned primarily by the founders and the institutional investors Inveready, Xesgalicia, Fitalent and Unirisco.

Public funding

Oncostellae has received funding through the program Conecta Pyme cofinanced by the Agencia Gallega de Innovación (GAIN) and the European Regional Development Fund (ERDF) and supported by the Consellería de Economía, Empleo e Industria (Xunta de Galicia) to execute the following projects:

“ONCOGALFARMA – Development of novel complementing therapies for the treatment of oncological diseases.” (IN852A 2014/1)

“NEOGALFARM – New anti-cancer drugs: Development of therapies directed at multiple therapeutic targets and combination treatments” (IN852A 2016/2)

“IO4COLON – Industrial research toward the discovery of novel immunotherapeutics for the treatment of colon cancer” (IN852A 2018/3)

INHIBIDORES NO-SISTEMICOS JAK PARA TRATAMIENTOS MÁS SEGUROS EN CU Y EC

«Proyecto CPP2021-009055, financiado por MCIN/AEI/10.13039/501100011033 y por la Unión Europea-NextGenerationEU/PRTR»

Entidades participantes: ONCOSTELLAE, S.L. y FUNDACION INSTITUTO DEINVESTIGACIÓN SANITARIA DE SANTIAGO

Período:01/02/2022 – 31/12/2023

Oncostellae has been a beneficiary, within the framework of the Recovery, Transformation and Resilience Plan and the State Program to Catalyze Innovation and Business Leadership of the State Plan for Scientific, Technical and Innovation Research 2021-2023, of the grant for the»Science and Innovation Missions Program» (EXP 00146129 / MIP-20211011)

Title: RESEARCH AND DEVELOPMENT OF THREE NEW THERAPIES DIRECTED FOR THE PERSONALIZED TREATMENT OF CANCER

«Subsidised by the CDTI and supported by the Ministerio de Ciencia e Innovación».

Oncostellae has got access to ERDF funds through the support from the Ministerio de Ciencia, Innovación y Universidades within the program “Retos” to execute the following project:

“Retos Colaboración – Research and Phase I development of novel kinase inhibitors for the treatment of diseases along the inflammation-fibrosis-cancer axis.” (RTC-2017-6403-1)

Oncostellae has received the following parcipative loans from the Empresa Nacional de Innovación S.A. (ENISA) supported by the Ministerio de Industria, Comercio y Turismo:

ENISA Emprendedor (2016)

ENISA Colaboración (2020)

Investors

Inveready is one of the leading early-stage venture capital companies in Spain, with five investment funds. Inveready invests in technology companies with high growth potential and innovative business models. Inveready has extensive experience in different areas, with more than 40 portfolio companies that are leaders in their respective sectors.

Fitalent (FIT Inversión en Talento SCR de Régimen Simplificado SL) es una sociedad de capital riesgo constituida a principios de 2011 e inscrita en el registro especial de la Comisión Nacional del Mercado de Valores (CNMV), que invierte en empresas de base tecnológica y con productos de éxito probado, cuyo principal activo sean las personas y el talento.

XesGalicia is a management company of venture capital firms that focuses on promoting the economic and industrial development and consolidation of businesses in Galicia, from four different investment vehicles. XesGalicia offers financing to different types of projects, from new enterprise initiatives to established industrial projects with a long history.

Unirisco is a private venture capital company promoting the creation of companies born in university, technology and R&D ecosystems that have a positive impact on the Spanish region of Galicia and on its surroundings.

Bio&Tech Smart Capital is the first Galician vertical investment fund specialized in the biotech, med tech, health tech, diagnostics and digital sectors oriented to life sciences.

This company is capitalized by INNVIERTE, AN INVESTMENT PROGRAM OF CDTI, E.P.E.

Esta empresa está capitalizada por INNVIERTE, INICIATIVA DE INVERSIÓN DE CDTI, E.P.E.